Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Acceleron Pharma, Inc.
Sponsor:
Information provided by (Responsible Party):
Acceleron Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01727336
First received: November 8, 2012
Last updated: November 22, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)